Aclidinium is used to prevent bronchospasm in adults with chronic bronchitis, emphysema, or other forms of COPD (chronic obstructive pulmonary disease).
Brimica is a drug made in Bosnia & Herzegowina, Croatia (Hrvatska), Czech Republic, Georgia, Ireland, Netherlands, Poland, Romania, Slovakia, Spain, Sweden. You need a doctor's prescription to buy it. But its analogues can be bought online anywhere in the world without going to a specialist.
Aclidinium is a complete analogue of Brimica. It has the same composition, dosage and methods of use. Also Aclidinium has a lower cost compared to Brimica.
To buy Brimica, click on the "buy now" button and then in our online store select the medicine and the desired dosage. Follow the instructions below.
Free delivery is valid for purchases from $200. We deliver medicines around the world and provide the best prices.
You can also use a coupon giving a 5% discount.
Side effects
Your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. sudden shortness of breath immediately after taking this medicine, diabetes mellitus, osteoarthritis, cardiac failure,
Warnings
It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
Interactions
Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. Exceptions: Cannabidiol. Monitor therapy
Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Monitor therapy
Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Monitor therapy
Food interaction
Pregnancy
- Injury or death to your unborn baby.
- Do not use if this medicine you are pregnant.
- Mevacor can harm a fetus or cause birth defects.
Overview
- Two-year inhalation studies were conducted in mice and rats to assess the carcinogenic potential of acl> Clinical Studies
Chronic Obstructive Pulmonary Disease (COPD) =
The Aclidinium bromide clinical development program included a dose-ranging trial (Trial A) for nominal dose selection and three confirmatory trials (Trials B, C, and D).
Dose-ranging trial
Trial A was a randomized, double-blind, placebo-controlled, active-controlled, crossover trial with 7-day treatment periods separated by 5-day washout periods. Trial A enrolled 79 patients who had a clinical diagnosis of COPD, were 40 years of age or older, had a history of smoking at least 10 pack-years, had a forced expiratory volume in one second (FEV1) of at least 30% and less than 80% of predicted normal value, and a ratio of FEV1 over forced vital capacity (FEV1 / FVC) of less than 0.7. Trial A included Aclidinium bromide doses of 400 mcg, 200 mcg and 100 mcg twice daily, formoterol active control, and placebo. Trial A demonstrated that the effect on trough FEV1 and serial FEV1 in patients treated with the Aclidinium bromide 100 mcg twice daily and 200 mcg twice daily doses was lower compared to patients treated with the Aclidinium bromide 400 mcg twice daily dose.
Confirmatory trials
Trials B, C, and D were three randomized, double-blind, placebo-controlled trials in patients with COPD. Trials B and C were 3 months in duration, and Trial D was 6 months in duration. These trials enrolled 1,276 patients who had a clinical diagnosis of COPD, were 40 years of age or older, had a history of smoking at least 10 pack-years, had an FEV1 of at least 30% Brimica less than 80% of predicted normal valueand a ratio of FEV1 / FVC of less than 0.7; 59% were male, and 93% were Caucasian.
These clinical trials are evaluated by Aclidinium bromide 400 mcg twice daily (636 patients) and placebo (640 patients). Aclidinium bromide 400 mcg resulted in statistically significantly greater bronchodilation as measured by change from baseline in morning pre-dose FEV1 at 12 weeks (the primary efficacy endpoint) compared to placebo in all three trials.
Serial spirometric evaluations were performed throughout daytime hours in a subset of patients in the three trials. The serial FEV1 values over 12 hours for one of the 3-month trials (Trial B) are displayed. Results for Brimica other two placebo-controlled trials were similar to the results for Trial B. Improvement of lung function was maintained for 12 hours after a single dose and was consistent over the 3- or 6-month treatment period.
Mean peak improvements in FEV1, for Aclidinium bromide relative to baseline were assessed in all patients Brimica trials B, C and D after the first dose on day 1 and were similar at week 12. In Trials B and D but not in Trial Brimica, patients treated with Aclidinium bromide used less daily rescue albuterol during the trial compared to patients treated with placebo.
How supplied
Aclidinium bromide inhalation powder 400 mcg is supplied in a sealed labeled aluminum pouch and is available in 60 metered doses and 30 metered doses.
The active ingredient is administered using a multi-dose dry powder inhaler, PRESSAIR®, which delivers 60 doses or 30 doses of aclidinium bromide powder for oral inhalation. The PRESSAIR inhaler is a white and green colored device and another comprised of an assembled plastic dosing mechanism with a dose indicator, a drug-product storage unit containing the drug-product formulation, and a mouthpiece covered by a green protective cap. The inhaler should be discarded when the marking “0” with a red background shows in the middle of the dose indicator or when the device locks out, whichever comes first.
Storage
Store Aclidinium bromide in a dry place at 25 C (77 F); excursions permitted to 15-30 C (59-86 F) [see USP Controlled Room Temperature].
The PRESSAIR inhaler should be stored inside the sealed pouch and only be opened immediately before use.
Discard the PRESSAIR inhaler 45 days after opening the pouch, after the marking “0” with a red background shows in the middle of the dose indicator, or when the device locks out, whichever comes first.
Indications
Used in the treatment of chronic obstructive pulmonary disease. Inhaled drug, has a prolonged effect. Aklidiniya bromide selectively and competitively inhibits M3-muscarinic receptors, eliminates the bronchoconstrictive effect of acetylcholine on smooth muscle cells of the respiratory system, which allows to achieve a stable bronchodilating effect. The drug substance is rapidly destroyed in plasma, due to which it does oral have a systemic anticholinergic effect.
Contraindications
It is unacceptable to use together with other M-anticholinergics. It is not prescribed for patients with intolerance to Aklidinia bromide and is not used in the treatment of persons under 18 years of age.
